With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...

Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing ...

Meghan Trainor has revealed she has Mounjaro to thank for her new look alongside diet and exercise but she's not the only one ...

Hims & Hers stirred the weight-loss waters by announcing it now offers prescriptions for Zepbound, Eli Lilly’s premium GLP-1 ...

A new analysis of FDA adverse event reports suggests a potential link between tirzepatide and thyroid cancer. Learn what this ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Livingwell Medical Center accepts most major insurance plans but also offers affordable self-pay rates for patients without ...

Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...